Prostatic disorders in the dog

Area of Science:

• Veterinary Medicine
• Canine Urology
• Oncology

Background:

• Canine prostatic disorders are common, including benign prostatic hypertrophy (BPH), prostatitis, cysts, and adenocarcinoma.
• BPH affects over 80% of intact male dogs older than 5 years, presenting with signs like bloody prostatic fluid, constipation, and difficult urination.
• BPH often co-occurs with other prostatic conditions such as infection, abscesses, cysts, and neoplasia.

Purpose of the Study:

• To summarize common canine prostatic disorders.
• To discuss the efficacy of finasteride in treating BPH and associated conditions.
• To explore the potential link between prostatic intraepithelial neoplasia (PIN) and adenocarcinoma in dogs.

Main Methods:

• Review of existing literature on canine prostatic diseases.
• Analysis of BPH pathophysiology and treatment responses.
• Examination of studies on canine prostatic adenocarcinoma and PIN.

Main Results:

• BPH is a prevalent, age-related condition in intact male dogs.
• Finasteride treatment effectively reduces BPH by inhibiting dihydrotestosterone production, leading to apoptosis and prostatic involution.
• Finasteride may benefit concurrent prostatic conditions, excluding neoplasia.
• Studies indicate a potential increased risk of prostatic adenocarcinoma in neutered dogs.
• Prostatic intraepithelial neoplasia (PIN) is frequently observed in older male dogs and may be a precursor to adenocarcinoma.

Conclusions:

• Finasteride is a viable treatment for canine BPH and associated disorders, except neoplasia.
• The relationship between neutering status and prostatic adenocarcinoma risk warrants further investigation.
• PIN may serve as a precursor to canine prostatic adenocarcinoma, similar to its role in humans.